Your session is about to expire
← Back to Search
Targeting Inflammation for Endometrial Cancer Prevention
N/A
Waitlist Available
Led By Mark E Sherman
Research Sponsored by Mayo Clinic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
* Women over the age of 18 years old undergoing hysterectomy for any benign indication or endometrial cancer
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion, up to 24 weeks
Awards & highlights
No Placebo-Only Group
Summary
This study examines risk assessment and identifies prevention strategies for endometrial cancer. Collecting samples of blood and urine and risk assessments from patients with benign conditions or endometrial cancer may help doctors learn if there is a relationship between chronic inflammation and increase in risk for endometrial cancer.
Eligible Conditions
- Uterine Cancer
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ through study completion, up to 24 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion, up to 24 weeks
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Levels of eicosanoids and specialized pro-resolving mediators (SPMs) in visceral adipose tissue (VAT)
Secondary study objectives
Ribonucleic acid (RNA) expression pathways related to inflammation in VAT
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Observational (questionnaire, biospecimen collection)Experimental Treatment2 Interventions
Patients complete a risk factor questionnaire over 15 minutes. Patients also undergo collection of blood and urine during pre-operative visit and collection of tissue samples at the time of surgery.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Biospecimen Collection
2004
Completed Phase 3
~2030
Find a Location
Who is running the clinical trial?
National Cancer Institute (NCI)NIH
13,958 Previous Clinical Trials
41,112,389 Total Patients Enrolled
Mayo ClinicLead Sponsor
3,362 Previous Clinical Trials
3,065,933 Total Patients Enrolled
Mark E ShermanPrincipal InvestigatorMayo Clinic
1 Previous Clinical Trials
33 Total Patients Enrolled
Mark E. Sherman, M.D.Principal InvestigatorMayo Clinic
1 Previous Clinical Trials
500 Total Patients Enrolled